Riskpilot← Back to searchSign inGet full accessPharmeko Sweden AB
ABActiveOrg 5592423890BollnäsWholesale of fruit and vegetables · NACE 4631Est. 20200 employees
Revenue 2024
SEK 2,4M
-90% vs 2023
EBITDA margin
-10.3%
-410% vs 2023
Equity ratio
1.0%
Financial strength
Net profit 2024
SEK -830K
-2319% vs 2023
| Revenue | SEK 2,4M | -90% |
| EBITDA | SEK -246K | -410% |
| Net profit | SEK -830K | -2319% |
| Total assets | SEK 3,7M | +12% |
| Equity | SEK 37K | -81% |
| Employees | 0 | — |
Legal name
Pharmeko Sweden AB
Org number
5592423890
Legal form
Aktiebolag
NACE code
4631 · Wholesale of fruit and vegetables
Founded
14 februari 2020
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva partihandel med vilda bär och svamp, färsk och fryst frukt för läkemedelsändamål samt livsmedelsmarknad. Partihandel med juice och andra livsmedelsprodukter samt därmed förenlig verksamhet.
Address
Bollnäs
Email
stefano.monesi@pharmeko-group.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 5 376 | 5 733 | 26 462 | 24 920 | 2 377 |
| Staff expenses | — | −276 | −630 | −610 | −498 |
| EBITDA | 383 | 279 | 971 | 79 | −246 |
| Depreciation & amort. | −156 | −277 | −513 | −346 | −613 |
| EBIT | 227 | 1 | 458 | −266 | −859 |
| Net financials | — | −0 | 4 | 97 | 16 |
| Profit before tax | 227 | 1 | 241 | 39 | −830 |
| Tax | −49 | −0 | — | −2 | — |
| Net profit | 178 | 1 | 241 | 37 | −830 |
| Item | 2021 | 2022 | 2023 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 964 | 2 814 | 3 377 | 3 293 | 3 699 |
| Equity | 203 | 29 | 270 | 197 | 37 |
| Long-term debt | 0 | — | 800 | 800 | 1 759 |
| Short-term debt | 761 | 2 785 | 2 086 | 2 283 | 1 903 |
| Total debt | 761 | 2 785 | 2 886 | 3 083 | 3 663 |
EBITDA margin
-10.3%
This company
15.8%
Market median
-165% vs market
20212024
Equity ratio
1.0%
This company
38.2%
Market median
-97% vs market
20212024
Return on equity
-2256.9%
This company
18.4%
Market median
-12366% vs market
20212024
Net profit margin
-34.9%
This company
8.1%
Market median
-531% vs market
20212024
Asset turnover
0.64×
This company
1.12×
Market median
-43% vs market
20212024
Debt / equity
99.57×
This company
0.62×
Market median
-15960% vs market
20212024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-06-01 – 2023-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-06-01 – 2023-05-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-06-01 – 2022-05-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-02-01 – 2021-05-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
TS Chief Auditor | Chief Auditor | 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Pharmeko Sweden AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Torbjörn Sven-Erik Arkenäs | Chief Auditor | 0 companies |
| Nanette Maria Brorén | Deputy Board Member | 0 companies |
| Stefano Monesi | Board of Directors | 0 companies |